At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 26, 2026 at 16:01 ET
Apogee Therapeutics completed a public offering of 5,750,000 shares at $70.00 per share, raising approximately $403 million in gross proceeds. The capital will support development of its clinical-stage biologics pipeline in inflammatory and immunology indications.
- Apogee Therapeutics closed an underwritten public offering of 5,750,000 shares of common stock
- Offering price was $70.00 per share, with full exercise of underwriters' option for 750,000 additional shares
- Aggregate gross proceeds were approximately $403 million before expenses
- Proceeds will be used to advance clinical development of Apogee's biologics pipeline, including zumilokibart (APG777) for atopic dermatitis, asthma, and EoE
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access